CRISPR-Edited Cell Lines: A New Era in Functional Oncology Research

Area of Science:

• Genomics
• Cancer Biology
• Immunotherapy

Background:

• CRISPR-Cas9 technology allows precise engineering of cancer cell lines.
• Understanding cancer cell responses to therapies is crucial for effective treatment.

Purpose of the Study:

• To highlight the advancements and applications of CRISPR-Cas9 in cancer research.
• To explore its role in drug resistance studies, immunotherapy, and tracking cancer evolution.

Main Methods:

• Utilizing CRISPR-Cas9 for gene knockouts (e.g., MED12) and modeling cancer processes (e.g., Epithelial-Mesenchymal Transition).
• Applying CRISPR to enhance Chimeric Antigen Receptor T (CAR-T) cell therapy by disrupting immune checkpoints (PD-1, CTLA-4).
• Conducting pharmacogenomic analysis across diverse cancer cell lines.

Main Results:

• Enabled detailed examination of cancer cell drug responses and resistance mechanisms.
• Facilitated the development of improved CAR-T cell therapies targeting specific antigens.
• Allowed tracking of cancer evolution, epigenetic changes, and resistance reversal strategies in NSCLC and ovarian cancer.

Conclusions:

• CRISPR-Cas9 is a powerful tool revolutionizing cancer research and therapeutic development.
• Future integration with AI, multi-omics, and organoids will advance precision oncology and treatment planning.